The profile of immune modulation by cannabidiol (CBD) involves deregulation of nuclear factor of activated T cells (NFAT)

Biochemical Pharmacology

Volumn 76, Issue 6, 2008, Pages 726-737

  Kaplan, Barbara L F ^a   Springs, Alison E B ^a   Kaminski, Norbert E ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

AP 1; Cannabinoid; Interferon gamma; Interleukin 2; NFAT

Indexed keywords

CALCIUM IONOPHORE; CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID DERIVATIVE; CANNABIS; CORN OIL; GAMMA INTERFERON; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; MESSENGER RNA; PHORBOL ESTER; TETRAHYDROCANNABINOL; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR NFAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL FUNCTION; CELL PROLIFERATION; CELL SURFACE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; FEEDING; FEMALE; HUMAN; HUMAN CELL; IMMUNE FUNCTION TEST; IMMUNE RESPONSE; IMMUNOGLOBULIN PRODUCING CELL; IMMUNOMODULATION; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHEEP ERYTHROCYTE; SPLEEN CELL; STATISTICAL ANALYSIS; T LYMPHOCYTE; TRANSCRIPTION REGULATION;

ANIMALS; CANNABIDIOL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOGLOBULIN M; IMMUNOLOGIC FACTORS; INTERFERON TYPE II; INTERLEUKIN-2; JURKAT CELLS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NFATC TRANSCRIPTION FACTORS; SPLEEN; T-LYMPHOCYTES;

EID: 50549105058     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.06.022     Document Type: Article

References (43)

1. Gaoni Y., and Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 86 8 (1964) 1646-1647
2. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., and Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (London) 346 (1990) 561-564
3. Munro S., Thomas K.L., and Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature (London) 365 (1993) 61-65
4. Srivastava M.D., Srivastava B.I., and Brouhard B. Delta9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmacology 40 3 (1998) 179-185
5. Malfait A.M., Gallily R., Sumariwalla P.F., Malik A.S., Andreakos E., Mechoulam R., et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA 97 17 (2000) 9561-9566
6. Costa B., Colleoni M., Conti S., Parolaro D., Franke C., Trovato A.E., et al. Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw. Naunyn Schmiedebergs Arch Pharmacol 369 3 (2004) 294-299
7. Vaney C., Heinzel-Gutenbrunner M., Jobin P., Tschopp F., Gattlen B., Hagen U., et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler 10 4 (2004) 417-424
8. Wade D.T., Makela P., Robson P., House H., and Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 10 4 (2004) 434-441
9. Kaplan B.L., Rockwell C.E., and Kaminski N.E. Evidence for cannabinoid receptor-dependent and -independent mechanisms of action in leukocytes. J Pharmacol Exp Ther 306 3 (2003) 1077-1085
10. Begg M., Pacher P., Batkai S., Osei-Hyiaman D., Offertaler L., Mo F.M., et al. Evidence for novel cannabinoid receptors. Pharmacol Ther 106 2 (2005) 133-145
11. Baker D., Pryce G., Davies W.L., and Hiley C.R. In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol Sci 27 1 (2006) 1-4
12. Rockwell C.E., and Kaminski N.E. A cyclooxygenase metabolite of anandamide causes inhibition of interleukin-2 secretion in murine splenocytes. J Pharmacol Exp Ther 311 2 (2004) 683-690
13. Rockwell C.E., Snider N.T., Thompson J., Vanden Heuvel J., and Kaminski N.E. Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor gamma independently of cannabinoid receptors 1 and 2. Mol Pharmacol 70 1 (2006) 101-111
14. Jarai Z., Wagner J.A., Varga K., Lake K.D., Compton D.R., Martin B.R., et al. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci USA 96 24 (1999) 14136-14141
15. Sacerdote P., Martucci C., Vaccani A., Bariselli F., Panerai A.E., Colombo A., et al. The nonpsychoactive component of marijuana cannabidiol modulates chemotaxis and IL-10 and IL-12 production of murine macrophages both in vivo and in vitro. J Neuroimmunol 159 1-2 (2005) 97-105
16. Kaminski N.E., and Holsapple M.P. Inhibition of macrophage accessory cell function in casein-treated B6C3F1 mice. J Immunol 139 6 (1987) 1804-1810
17. Jerne N.K., and Nordin A.A. Plaque formation in agar by single antibody-producing cells. Science 140 (1963) 405
18. Herring A.C., Koh W.S., and Kaminski N.E. Inhibition of the cyclic AMP signaling cascade and nuclear factor binding to CRE and kappaB elements by cannabinol, a minimally CNS-active cannabinoid. Biochem Pharmacol 55 7 (1998) 1013-1023
19. Schatz A.R., Koh W.S., and Kaminski N.E. Δ9-tetrahydrocanabinol selectively inhibits T-cell dependent humoral immune responses through direct inhibition of accessory T-cell function. Immunopharmacology 26 (1993) 129-137
20. Sica A., Dorman L., Viggiano V., Cippitelli M., Ghosh P., Rice N., et al. Interaction of NF-kappaB and NFAT with the interferon-gamma promoter. J Biol Chem 272 48 (1997) 30412-30420
21. Sweetser M.T., Hoey T., Sun Y.L., Weaver W.M., Price G.A., and Wilson C.B. The roles of nuclear factor of activated T cells and ying-yang 1 in activation-induced expression of the interferon-gamma promoter in T cells. J Biol Chem 273 52 (1998) 34775-34783
22. Shaw J.P., Utz P.J., Durand D.B., Toole J.J., Emmel E.A., and Crabtree G.R. Identification of a putative regulator of early T cell activation genes. Science 241 4862 (1988) 202-205
23. Jain J., McCaffrey P.G., Miner Z., Kerppola T.K., Lambert J.N., Verdine G.L., et al. The T-cell transcription factor NFATp is a substrate for calcineurin and interacts with Fos and Jun. Nature 365 6444 (1993) 352-355
24. Faubert B.L., and Kaminski N.E. AP-1 activity is negatively regulated by cannabinol through inhibition of its protein components, c-fos and c-jun. J Leukoc Biol 67 2 (2000) 259-266
25. Ouyang Y., Hwang S.G., Han S.H., and Kaminski N.E. Suppression of interleukin-2 by the putative endogenous cannabinoid 2-arachidonyl-glycerol is mediated through down-regulation of the nuclear factor of activated T cells. Mol Pharmacol 53 4 (1998) 676-683
26. Yea S.S., Yang K.H., and Kaminski N.E. Role of nuclear factor of activated T-cells and activator protein-1 in the inhibition of interleukin-2 gene transcription by cannabinol in EL4 T-cells. J Pharmacol Exp Ther 292 2 (2000) 597-605
27. Condie R., Herring A., Koh W.S., Lee M., and Kaminski N.E. Cannabinoid inhibition of adenylate cyclase-mediated signal transduction and IL-2 expression in the murine T-cell line, EL4.IL-2. J Biol Chem 271 (1996) 13175-13183
28. Kaplan B.L., Ouyang Y., Herring A., Yea S.S., Razdan R., and Kaminski N.E. Inhibition of leukocyte function and interleukin-2 gene expression by 2-methylarachidonyl-(2′-fluoroethyl)amide, a stable congener of the endogenous cannabinoid receptor ligand anandamide. Toxicol Appl Pharmacol 205 2 (2005) 107-115
29. Kaplan B.L., Ouyang Y., Rockwell C.E., Rao G.K., and Kaminski N.E. 2-Arachidonoyl-glycerol suppresses interferon-gamma production in phorbol ester/ionomycin-activated mouse splenocytes independent of CB1 or CB2. J Leukoc Biol 77 6 (2005) 966-974
30. Drysdale A.J., Ryan D., Pertwee R.G., and Platt B. Cannabidiol-induced intracellular Ca(2+) elevations in hippocampal cells. Neuropharmacology 50 5 (2006) 621-631
31. Rao G.K., and Kaminski N.E. Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship. J Pharmacol Exp Ther 317 2 (2006) 820-829
32. Ryberg E., Larsson N., Sjogren S., Hjorth S., Hermansson N.O., Leonova J., et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152 7 (2007) 1092-1101
33. Bisogno T., Hanus L., De Petrocellis L., Tchilibon S., Ponde D.E., Brandi I., et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134 4 (2001) 845-852
34. Mishima K., Hayakawa K., Abe K., Ikeda T., Egashira N., Iwasaki K., et al. Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism. Stroke 36 5 (2005) 1077-1082
35. Russo E.B., Burnett A., Hall B., and Parker K.K. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 30 8 (2005) 1037-1043
36. Carrier E.J., Auchampach J.A., and Hillard C.J. Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci USA 103 20 (2006) 7895-7900
37. Macian F. NFAT proteins: key regulators of T-cell development and function. Nat Rev Immunol 5 6 (2005) 472-484
38. Schuh K., Twardzik T., Kneitz B., Heyer J., Schimpl A., and Serfling E. The interleukin 2 receptor alpha chain/CD25 promoter is a target for nuclear factor of activated T cells. J Exp Med 188 7 (1998) 1369-1373
39. Matsuguchi T., Takagi K., Musikacharoen T., and Yoshikai Y. Gene expressions of lipopolysaccharide receptors, toll-like receptors 2 and 4, are differently regulated in mouse T lymphocytes. Blood 95 4 (2000) 1378-1385
40. Ulmer A.J., Flad H., Rietschel T., and Mattern T. Induction of proliferation and cytokine production in human T lymphocytes by lipopolysaccharide (LPS). Toxicology 152 1-3 (2000) 37-45
41. Zimmerman S., Zimmerman A.M., Cameron I.L., and Laurence H.L. delta1-tetrahydrocannabinol, cannabidiol and cannabinol effects on the immune response of mice. Pharmacology 15 1 (1977) 10-23
42. Jan T.R., Su S.T., Wu H.Y., and Liao M.H. Suppressive effects of cannabidiol on antigen-specific antibody production and functional activity of splenocytes in ovalbumin-sensitized BALB/c mice. Int Immunopharmacol 7 6 (2007) 773-780
43. Springs AE, Karmaus PW, Crawford RB, Kaplan BL, Kaminski NE. Effects of targeted deletion of cannabinoid receptors CB1 and CB2 on immune competence and sensitivity to immune modulation by Δ9-tetrahydrocannabinol. J Leukoc Biol 2008; in press.